A large number of both in vitro and in vivo experiments suggest that therapeutic targeting of both CR3 and CR4 could potentially produce effects such as lowering of autoimmune inflammation (141) or enhance the effects of anti-cancer vaccination (142). The gene discussed is CRIPTO3; the disease is cancer.